We will now discuss the findings supporting the implication of MCL-1 in an array of solid and hematological tumors and review the potential combinations of MCL-1 inhibitors with preexisting therapeutic options. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.